Nasdaq
$0.9806▼ 0.68%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $47.7MShares out 48.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 9.22After-hours26.09.23 06:04S-4Offering#●●●#●●●#●●●
Werewolf Therapeutics, Inc.
Werewolf Therapeutics has entered into a definitive merger agreement with Ambros Therapeutics, under which Ambros will become a wholly owned subsidiary and the combined company will be renamed Ambros Therapeutics, Inc. The transaction includes a concurrent $150 million PIPE financing, and the combined company is expected to trade on Nasdaq under the ticker symbol 'AMBX' upon completion.…more
$0.9806-0.68%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.21Regular26.09.22 00:11SCHEDULE 13GOwnership
Werewolf Therapeutics, Inc.
Peter Moll has filed a Schedule 13G regarding his beneficial ownership of Werewolf Therapeutics, Inc. This filing serves as an official disclosure of the investor's equity stake in the company.…more
$0.9806-0.68%vs prev closeView filingShare - 8.21Pre-market26.08.21 22:12425Other
Werewolf Therapeutics, Inc.
Werewolf Therapeutics entered into a definitive merger agreement with Ambros Therapeutics on August 21, 2026, with Ambros stockholders expected to own approximately 71.7% of the combined company post-closing. The transaction includes a concurrent $150 million PIPE financing and the issuance of Contingent Value Rights (CVRs) to existing Werewolf stockholders related to its legacy assets, WTX-124 and WTX-330.…more
$0.9806-0.68%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.21Regular26.08.21 22:33#●●●#●●●#●●●
Werewolf Therapeutics to Merge with Ambros, Secures $150M Financing
Werewolf Therapeutics has agreed to merge with Ambros Therapeutics in an all-stock deal while securing $150 million in private placement financing. The combined entity will focus on developing the pain treatment neridronate, with cash runway extended into the first half of 2029.…more
$0.9806-0.68%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.21Regular26.08.21 22:30
●●●●●●●● ●●●●● ●●●●●●
Werewolf Therapeutics will merge with Ambros Therapeutics in a $500 million all-stock deal and secure $150 million in new funding to advance drug development. The transaction results in significant equity dilution for existing shareholders and a rebranding to Ambros Therapeutics.…more
$0.9806-0.68%vs prev closeShareBenzinga - 8.21Pre-market26.08.21 21:15
●●●●●●●● ●●●●● ●●●●●●
Trading of Werewolf Therapeutics (HOWL) shares was temporarily halted and subsequently resumed. This announcement reflects standard regulatory procedures for market trading pauses.…more
$0.9806-0.68%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report